The BD Onclarity HPV Assay is a clinically validated, PCR-based molecular test designed for accurate detection and extended genotyping of high-risk human papillomavirus (HPV) types associated with cervical cancer. It simultaneously detects 14 high-risk HPV genotypes, providing individual identification for key types such as HPV 16, 18, and others, enabling precise risk stratification and patient management. With automated processing on BD platforms, internal cellular controls, and E6/E7 gene targeting, it minimizes false results while supporting efficient, guideline-based cervical cancer screening programs.